Nearest gene: RFX6
Most severe consequence: frameshift variant
AF 2.0e-3(ranges from 1.5e-3 to 2.2e-3 across all phenotypes)
AF in gnomAD genomes 2.1: FIN 2.9e-3, POPMAX ., FIN enrichment vs. NFEE: No NFEE in gnomAD
INFO 0.833 (ranges in genotyping batches from 0.572 to 1.000 )
Number of alt homozygotes: 1
View in Open Targets , gnomAD , UCSC , GWAS Catalog , dbSNP
category | phenotype | beta (se) | p-value | -log10(p) | af cases | af controls | number of samples | UKBB | UKBB N samples |
---|---|---|---|---|---|---|---|---|---|
IV Endocrine, nutritional and metabolic diseases (E4_) | Type 2 diabetes | 0.65 | 4.1e-15 | 14.4 | 2.9e-3 | 1.8e-3 | 49303 / 255466 | NA | NA |
IV Endocrine, nutritional and metabolic diseases (E4_) | Type 2 diabetes with other specified/multiple/unspecified complications | 0.72 | 6.5e-15 | 14.2 | 3.0e-3 | 1.8e-3 | 35857 / 255466 | NA | NA |
Diabetes endpoints | Diabetes, insuline treatment (Kela reimbursement) (more control exclusions) | 0.66 | 9.0e-15 | 14.0 | 3.0e-3 | 1.8e-3 | 41247 / 255500 | NA | NA |
Diabetes endpoints | Diabetes, varying definitions | 0.61 | 1.0e-14 | 14.0 | 2.9e-3 | 1.8e-3 | 53388 / 255766 | NA | NA |
IV Endocrine, nutritional and metabolic diseases (E4_) | Diabetes mellitus | 0.61 | 1.1e-14 | 13.9 | 2.9e-3 | 1.8e-3 | 53688 / 255466 | NA | NA |
Diabetes endpoints | Diabetes, insuline treatment (Kela reimbursement) | 0.64 | 2.0e-14 | 13.7 | 3.0e-3 | 1.8e-3 | 41247 / 267907 | NA | NA |
Diabetes endpoints | Type 2 diabetes, definitions combined, including avohilmo | 0.63 | 1.5e-13 | 12.8 | 2.8e-3 | 1.8e-3 | 46818 / 253665 | NA | NA |
IV Endocrine, nutritional and metabolic diseases (E4_) | Type 2 diabetes, strict (exclude DM1) | 0.61 | 3.0e-12 | 11.5 | 2.8e-3 | 1.8e-3 | 44266 / 256217 | NA | NA |
Diabetes endpoints | Type 2 diabetes, wide definition | 0.72 | 3.2e-12 | 11.5 | 3.0e-3 | 1.8e-3 | 28960 / 257444 | NA | NA |
Diabetes endpoints | Type 2 diabetes, definitions combined | 0.61 | 3.3e-12 | 11.5 | 2.8e-3 | 1.8e-3 | 44313 / 255449 | NA | NA |